Head of Data Management beats his personal best in the 2006 London Marathon

Posted:
28
April 2006

Adam Walker, Head of Richmond's Data Management service completed the 2006 London Marathon in 4 hours and 24 minutes - his best time in 3 years.Richmond Pharmacology Ltd sponsored Adam £500 to complete the run and in total he has raised £3,000 for Bliss, the premature baby charity.Training for this year's run started in December 2005, although he did have his setbacks."In February I was admitted to hospital and was put on a drip for 2 days with a mystery illness this happened just 6 weeks before the marathon. Fortunately I made a rapid recovery and was able to resume training."Next year he aims to complete the course in under 4 hours!"By mile 20 I had a massive burst of energy and pushed on for the last 6 miles - sprinting to the finishing line!"The charity Bliss is dedicated to caring for premature babies: "This is the third consecutive year I have run to support Bliss and over the 3 years I have raised more than £10,000 for the charity. My daughter Amelie Grace was born 6 weeks prematurely and was in intensive care at the Sussex County Hospital, Brighton for 4 weeks. I am very grateful that Amelie was able to make a full recovery. I will continue to raise money for Bliss to help other families who find themselves in the same position"To find out more about Bliss visit: www.bliss.org.ukTo sponsor Adam, visit: www.justgiving.com/adamwalker_londonmarathon2006.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more